JP2014177455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014177455A5 JP2014177455A5 JP2014043175A JP2014043175A JP2014177455A5 JP 2014177455 A5 JP2014177455 A5 JP 2014177455A5 JP 2014043175 A JP2014043175 A JP 2014043175A JP 2014043175 A JP2014043175 A JP 2014043175A JP 2014177455 A5 JP2014177455 A5 JP 2014177455A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- kit
- cda
- substrate drug
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 102100003292 CDA Human genes 0.000 claims 13
- 108010031325 EC 3.5.4.5 Proteins 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drugs Drugs 0.000 claims 8
- 239000000758 substrate Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229960002756 Azacitidine Drugs 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 229960003603 decitabine Drugs 0.000 claims 2
- 230000004059 degradation Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- AZYOZBIYZJGKSO-XKBRQERYSA-N 4-amino-1-[(2R,4S,5S)-5-[fluoro(hydroxy)methyl]-4-hydroxyoxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](C(O)F)[C@@H](O)C1 AZYOZBIYZJGKSO-XKBRQERYSA-N 0.000 claims 1
- NGGRGTWYSXYVDK-RRKCRQDMSA-N 4-amino-5-chloro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Cl)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 NGGRGTWYSXYVDK-RRKCRQDMSA-N 0.000 claims 1
- GFFXZLZWLOBBLO-ASKVSEFXSA-N Tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 claims 1
- 229950006410 Tezacitabine Drugs 0.000 claims 1
- -1 ara-C Chemical compound 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
Claims (15)
- CDAによるCDA基質薬剤の分解を阻害するための、請求項1に記載の医薬組成物。
- 請求項1〜4のいずれか1項に記載の医薬組成物を含む、キット。
- 5−アザシチジン、ゲムシタビン、アラ−C、テザシタビン、5’−フルオロ−2’−デオキシシチジン、およびシトクロルからなる群から選択されるCDA基質薬剤である第二の化合物を更に含む、請求項5に記載のキット。
- CDA基質薬剤である第二の化合物を更に含み、前記CDA基質薬剤がデシタビンではない、請求項5に記載のキット。
- CDA基質薬剤である第二の化合物を更に含み、前記CDA基質薬剤がデシタビンである、請求項5に記載のキット。
- 前記CDA基質薬剤が、5−アザシチジン、ゲムシタビンまたはアラ−Cである、請求項6または7に記載のキット。
- 前記式Iの化合物及び前記第二の化合物が別個の容器中にある、または前記式Iの化合物及び前記第二の化合物が単位剤形中にある、請求項6〜9のいずれか1項に記載のキット。
- 請求項1〜4のいずれか1項に記載の医薬組成物の単位剤形を含む、キット。
- 更に情報を含む、請求項5〜11のいずれか1項に記載のキット。
- CDAを阻害するための、請求項5〜11のいずれか1項に記載のキット。
- CDAによるCDA基質薬剤の分解を阻害するための、請求項5〜11のいずれか1項に記載のキット。
- 癌を治療するための、請求項5〜11のいずれか1項に記載のキット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98039707P | 2007-10-16 | 2007-10-16 | |
US60/980,397 | 2007-10-16 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010530110A Division JP5496899B2 (ja) | 2007-10-16 | 2008-10-16 | シチジンデアミナーゼ阻害剤としての2’−フルオロ−2’−デオキシテトラヒドロウリジン |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014177455A JP2014177455A (ja) | 2014-09-25 |
JP2014177455A5 true JP2014177455A5 (ja) | 2015-02-05 |
JP5859588B2 JP5859588B2 (ja) | 2016-02-10 |
Family
ID=40251685
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010530110A Active JP5496899B2 (ja) | 2007-10-16 | 2008-10-16 | シチジンデアミナーゼ阻害剤としての2’−フルオロ−2’−デオキシテトラヒドロウリジン |
JP2014043175A Active JP5859588B2 (ja) | 2007-10-16 | 2014-03-05 | シチジンデアミナーゼ阻害剤としての2’−フルオロ−2’−デオキシテトラヒドロウリジン |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010530110A Active JP5496899B2 (ja) | 2007-10-16 | 2008-10-16 | シチジンデアミナーゼ阻害剤としての2’−フルオロ−2’−デオキシテトラヒドロウリジン |
Country Status (39)
Country | Link |
---|---|
US (4) | US8268800B2 (ja) |
EP (2) | EP2447272B1 (ja) |
JP (2) | JP5496899B2 (ja) |
KR (1) | KR101543049B1 (ja) |
CN (1) | CN101827856B (ja) |
AT (1) | ATE548374T1 (ja) |
BR (1) | BRPI0818672B8 (ja) |
CA (1) | CA2702274C (ja) |
CO (1) | CO6270330A2 (ja) |
CR (1) | CR11427A (ja) |
CY (3) | CY1112781T1 (ja) |
DK (1) | DK2207786T3 (ja) |
EA (1) | EA018757B1 (ja) |
EC (1) | ECSP10010095A (ja) |
ES (2) | ES2384011T3 (ja) |
FI (2) | FIC20230039I1 (ja) |
FR (2) | FR23C1051I1 (ja) |
GT (1) | GT201000088A (ja) |
HK (1) | HK1146410A1 (ja) |
HR (1) | HRP20120419T1 (ja) |
HU (2) | HUS2300045I1 (ja) |
IL (1) | IL204732A (ja) |
JO (1) | JO2778B1 (ja) |
ME (1) | ME00997B (ja) |
MX (1) | MX2010004109A (ja) |
MY (1) | MY147970A (ja) |
NI (1) | NI201000055A (ja) |
NL (1) | NL301256I2 (ja) |
NO (2) | NO2023047I1 (ja) |
NZ (1) | NZ584229A (ja) |
PL (1) | PL2207786T3 (ja) |
PT (1) | PT2207786E (ja) |
RS (1) | RS52323B (ja) |
SA (1) | SA08290661B1 (ja) |
SI (1) | SI2207786T1 (ja) |
TW (1) | TWI445539B (ja) |
UA (1) | UA99476C2 (ja) |
WO (1) | WO2009052287A1 (ja) |
ZA (1) | ZA201002178B (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
JO2778B1 (en) * | 2007-10-16 | 2014-03-15 | ايساي انك | Certain vehicles, installations and methods |
MX363023B (es) | 2008-05-15 | 2019-03-05 | Celgene Corp | Formulaciones orales de analogos de citidina y metodos para usar los mismos. |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
US20100055047A1 (en) * | 2008-08-26 | 2010-03-04 | Yiyu Zou | Methods for treating bronchial premalignancy and lung cancer |
TW201031675A (en) * | 2008-12-23 | 2010-09-01 | Pharmasset Inc | Synthesis of purine nucleosides |
TWI503121B (zh) * | 2009-04-06 | 2015-10-11 | Otsuka Pharma Co Ltd | 用以治療癌症之組成物及方法 |
US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
EP2416781B1 (en) * | 2009-04-06 | 2017-03-08 | Otsuka Pharmaceutical Co., Ltd. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
AU2010234637B2 (en) * | 2009-04-06 | 2016-05-12 | Otsuka Pharmaceutical Co., Ltd. | (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer |
GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
UY33311A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidatos de nucleosidos |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
MX363205B (es) * | 2013-10-29 | 2019-03-13 | Otsuka Pharma Co Ltd | Ruta sintetica para obtener 2'-deoxi-2',2'-difluorotetrahidrouridi nas. |
KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
ES2940302T3 (es) | 2014-08-22 | 2023-05-05 | Celgene Corp | Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos |
EP3383406B1 (en) | 2015-12-03 | 2021-10-20 | Epidestiny, Inc. | Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof |
WO2017158396A1 (en) | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cytidine deaminase inhibitors for the treatment of pancreatic cancer |
KR20200118827A (ko) | 2018-02-02 | 2020-10-16 | 마베릭스 온콜로지, 잉크. | 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트 |
US11224610B2 (en) * | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
JP7433662B2 (ja) * | 2018-10-19 | 2024-02-20 | インターオリゴ・コーポレイション | 治療効能を改善した核酸変形体及びそれを含む抗癌用薬学組成物 |
KR102280330B1 (ko) * | 2018-10-19 | 2021-07-21 | 인터올리고 주식회사 | 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물 |
KR20220078619A (ko) | 2019-10-08 | 2022-06-10 | 오츠카 세이야쿠 가부시키가이샤 | 고순도의 2'-데옥시-2',2'-디플루오로테트라히드로우리딘 및 그의 제조 방법 |
KR20220145815A (ko) * | 2020-02-25 | 2022-10-31 | 오츠카 세이야쿠 가부시키가이샤 | 조합 데시타빈 및 세다주리딘 고체 경구 투여 형태 |
AU2022244240A1 (en) * | 2021-03-26 | 2023-10-05 | The Cleveland Clinic Foundation | Treatment of rna virus infection with a cytidine deaminase inhibitor |
US20240279266A1 (en) * | 2021-05-29 | 2024-08-22 | Msn Laboratories Private Limited, R&D Center | An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds |
KR20240108406A (ko) | 2021-10-19 | 2024-07-09 | 아키라바이오, 인크. | 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도 |
WO2023076332A1 (en) * | 2021-11-01 | 2023-05-04 | St. John's University | Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor |
US20230271996A1 (en) * | 2021-12-25 | 2023-08-31 | Scinopharm Taiwan, Ltd. | Process for preparing cedazuridine |
TW202410893A (zh) | 2022-08-31 | 2024-03-16 | 日商大塚製藥股份有限公司 | 用於治療t細胞淋巴瘤之結合治療 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017606A (en) * | 1973-10-04 | 1977-04-12 | The Upjohn Company | Organic compounds and process |
US4210638A (en) * | 1978-03-17 | 1980-07-01 | Pcr, Inc. | Antiviral composition and method of treating virus diseases |
US4275057A (en) | 1980-01-28 | 1981-06-23 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Seven-membered ring compounds as inhibitors of cytidine deaminase |
US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
DE3481172D1 (de) | 1983-10-26 | 1990-03-08 | Sheldon B Greer | Verfahren und materialien zum empfindlichmachen eines neoplastischen gewebes vor strahlung. |
IL77133A (en) | 1984-12-04 | 1991-01-31 | Lilly Co Eli | Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation |
US4965374A (en) | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
US5968914A (en) | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
CA2086233C (en) | 1991-04-23 | 1995-10-17 | Wendy Oglevee-O'donovan | In vitro leaf petiole multiplication of pelargoniums |
FR2682112B1 (fr) | 1991-10-08 | 1993-12-10 | Commissariat A Energie Atomique | Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection. |
US5426183A (en) | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5594124A (en) | 1992-06-22 | 1997-01-14 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof |
US5821357A (en) | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
US5606048A (en) | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
WO1994019362A1 (en) | 1993-02-23 | 1994-09-01 | City Of Hope | 4-ethoxy 5-fluoro 2'deoxyuridine |
WO1994026761A1 (en) | 1993-05-14 | 1994-11-24 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
GB9311252D0 (en) | 1993-06-01 | 1993-07-21 | Hafslund Nycomed As | Cell growth regualtors |
US5637688A (en) | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
US5521294A (en) | 1995-01-18 | 1996-05-28 | Eli Lilly And Company | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides |
AU5300396A (en) * | 1995-03-01 | 1996-09-18 | Human Gene Therapy Research Institute | Radiation enhanced gene therapy for treatment of tumors |
US6001994A (en) | 1995-12-13 | 1999-12-14 | Eli Lilly And Company | Process for making gemcitabine hydrochloride |
US5760208A (en) | 1996-08-14 | 1998-06-02 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Process to prepare pyrimidine nucleosides |
DE60030842T2 (de) | 1999-03-01 | 2007-05-10 | Halogenetics Inc., Aventura | VERWENDUNG VON ZUSAMMENSETZUNGEN ENTHALTEND CldC ALS STRAHLUNGSSENSIBILISATOREN IN DER BEHANDLUNG VON NEOPLASTISCHEN ERKRANKUNGEN |
US6933287B1 (en) | 1999-03-01 | 2005-08-23 | Sheldon B. Greer | Dramatic simplification of a method to treat neoplastic disease by radiation |
EP1207783A1 (en) | 1999-08-26 | 2002-05-29 | Aortech International PLC | Improvements relating to catheter positioning |
US6462191B1 (en) | 2000-07-13 | 2002-10-08 | Air Products And Chemicals, Inc. | Synthesis of 2-deoxy-2-fluoro-arabinose derivatives |
US7125983B2 (en) | 2000-11-29 | 2006-10-24 | Mitsui Chemicals, Inc. | L-nucleic acid derivatives and process for the synthesis thereof |
JP4458746B2 (ja) | 2001-01-16 | 2010-04-28 | グラクソ グループ リミテッド | 癌の治療方法 |
WO2002094844A2 (en) | 2001-05-18 | 2002-11-28 | Rakesh Kumar | Antiviral nucleosides |
US8207142B2 (en) * | 2001-07-31 | 2012-06-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibitor of DNA methylation |
AU2003217402A1 (en) | 2002-02-14 | 2003-09-04 | Pharmasset Inc | Modified fluorinated nucleoside analogues |
US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
AU2003278904A1 (en) | 2002-09-24 | 2004-04-19 | Kornis Pharmaceuticals, Incorporated | 1, 3, 5-triazines for treatment of viral diseases |
US7265096B2 (en) | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
US8158770B2 (en) | 2004-05-06 | 2012-04-17 | University Of Rochester | Content dependent inhibitors of cytidine deaminases and uses thereof |
US20060014949A1 (en) | 2004-07-13 | 2006-01-19 | Supergen Inc. | Compositions and formulations of decitabine polymorphs and methods of use thereof |
TW200606159A (en) | 2004-07-30 | 2006-02-16 | Pharmaessentia Corp | Stereoselective synthesis of β-nucleosides |
CA2586687A1 (en) | 2004-12-08 | 2006-06-15 | Sicor Inc. | Difluoronucleosides and process for preparation thereof |
WO2008085611A2 (en) * | 2006-11-27 | 2008-07-17 | University Of Miami | Designer theraphy of pancreatic tumors |
WO2009021551A1 (en) | 2007-08-13 | 2009-02-19 | Universite De La Mediterranee | A method for assessing the risk of toxicity in a chemotherapy |
JO2778B1 (en) * | 2007-10-16 | 2014-03-15 | ايساي انك | Certain vehicles, installations and methods |
WO2010047698A1 (en) | 2008-10-22 | 2010-04-29 | University Of Alabama At Birmingham | Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases |
US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
EP2416781B1 (en) | 2009-04-06 | 2017-03-08 | Otsuka Pharmaceutical Co., Ltd. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
TWI503121B (zh) | 2009-04-06 | 2015-10-11 | Otsuka Pharma Co Ltd | 用以治療癌症之組成物及方法 |
AU2010234637B2 (en) | 2009-04-06 | 2016-05-12 | Otsuka Pharmaceutical Co., Ltd. | (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer |
-
2008
- 2008-10-14 JO JO2008459A patent/JO2778B1/en active
- 2008-10-15 TW TW097139594A patent/TWI445539B/zh active
- 2008-10-16 ES ES08840633T patent/ES2384011T3/es active Active
- 2008-10-16 AT AT08840633T patent/ATE548374T1/de active
- 2008-10-16 SI SI200830624T patent/SI2207786T1/sl unknown
- 2008-10-16 PT PT08840633T patent/PT2207786E/pt unknown
- 2008-10-16 EA EA201000642A patent/EA018757B1/ru unknown
- 2008-10-16 CA CA2702274A patent/CA2702274C/en active Active
- 2008-10-16 EP EP12151552.2A patent/EP2447272B1/en active Active
- 2008-10-16 KR KR1020107010621A patent/KR101543049B1/ko active IP Right Grant
- 2008-10-16 JP JP2010530110A patent/JP5496899B2/ja active Active
- 2008-10-16 BR BRPI0818672A patent/BRPI0818672B8/pt active IP Right Grant
- 2008-10-16 PL PL08840633T patent/PL2207786T3/pl unknown
- 2008-10-16 MX MX2010004109A patent/MX2010004109A/es active IP Right Grant
- 2008-10-16 WO PCT/US2008/080163 patent/WO2009052287A1/en active Application Filing
- 2008-10-16 RS RS20120232A patent/RS52323B/en unknown
- 2008-10-16 MY MYPI2010001528A patent/MY147970A/en unknown
- 2008-10-16 ES ES12151552.2T patent/ES2616566T3/es active Active
- 2008-10-16 ME MEP-2010-68A patent/ME00997B/me unknown
- 2008-10-16 UA UAA201003977A patent/UA99476C2/ru unknown
- 2008-10-16 NZ NZ584229A patent/NZ584229A/en unknown
- 2008-10-16 EP EP08840633A patent/EP2207786B1/en active Active
- 2008-10-16 US US12/252,961 patent/US8268800B2/en active Active
- 2008-10-16 CN CN2008801117195A patent/CN101827856B/zh active Active
- 2008-10-16 DK DK08840633.5T patent/DK2207786T3/da active
- 2008-10-18 SA SA08290661A patent/SA08290661B1/ar unknown
-
2010
- 2010-01-26 ZA ZA2010/02178A patent/ZA201002178B/en unknown
- 2010-03-25 IL IL204732A patent/IL204732A/en active IP Right Grant
- 2010-04-09 EC EC2010010095A patent/ECSP10010095A/es unknown
- 2010-04-12 GT GT201000088A patent/GT201000088A/es unknown
- 2010-04-14 NI NI201000055A patent/NI201000055A/es unknown
- 2010-05-12 CR CR11427A patent/CR11427A/es unknown
- 2010-05-13 CO CO10057462A patent/CO6270330A2/es active IP Right Grant
-
2011
- 2011-01-20 HK HK11100565.2A patent/HK1146410A1/xx unknown
-
2012
- 2012-05-16 HR HRP20120419AT patent/HRP20120419T1/hr unknown
- 2012-05-24 CY CY20121100467T patent/CY1112781T1/el unknown
- 2012-07-24 US US13/556,404 patent/US8618075B2/en active Active
-
2013
- 2013-11-25 US US14/088,465 patent/US8951987B2/en active Active
-
2014
- 2014-03-05 JP JP2014043175A patent/JP5859588B2/ja active Active
- 2014-12-29 US US14/584,437 patent/US9567363B2/en active Active
-
2023
- 2023-12-21 NO NO2023047C patent/NO2023047I1/no unknown
- 2023-12-21 NO NO2023048C patent/NO2023048I1/no unknown
- 2023-12-21 HU HUS2300045C patent/HUS2300045I1/hu unknown
- 2023-12-21 HU HUS2300044C patent/HUS2300044I1/hu unknown
- 2023-12-22 CY CY2023028C patent/CY2023028I1/el unknown
- 2023-12-22 FI FIC20230039C patent/FIC20230039I1/fi unknown
- 2023-12-22 CY CY2023029C patent/CY2023029I1/el unknown
- 2023-12-22 FI FIC20230040C patent/FIC20230040I1/fi unknown
- 2023-12-26 FR FR23C1051C patent/FR23C1051I1/fr active Active
- 2023-12-26 FR FR23C1052C patent/FR23C1052I1/fr active Active
- 2023-12-27 NL NL301256C patent/NL301256I2/nl unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014177455A5 (ja) | ||
JP2017186358A5 (ja) | ||
JP2018024682A5 (ja) | ||
JP2016518337A5 (ja) | ||
JP2015078230A5 (ja) | ||
JP2013518107A5 (ja) | ||
JP2014221779A5 (ja) | ||
JP2016521119A5 (ja) | ||
EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
EA201890494A1 (ru) | Способы лечения вирусных инфекций arenaviridae и coronaviridae | |
JP2017524735A5 (ja) | ||
JP2011500713A5 (ja) | ||
EA201592075A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
UA113980C2 (uk) | Заміщені нуклеозиди, нуклеотиди і їх аналоги | |
JP2016508134A5 (ja) | ||
JP2017506627A5 (ja) | ||
JP2013032389A5 (ja) | ||
JP2009545527A5 (ja) | ||
JP2014507446A5 (ja) | ||
JP2016540015A5 (ja) | ||
JP2011527299A5 (ja) | ||
JP2017518250A5 (ja) | ||
JP2011518153A5 (ja) | ||
MA40781A (fr) | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale | |
PH12015502589A1 (en) | 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives |